Kairos Pharma's ENV-105 Interim Data Shows 17.7-Month Progression-Free Survival in Prostate Cancer Trial

By The Building Texas Show•
Kairos Pharma presented interim Phase 2 results showing ENV-105 plus apalutamide extended median progression-free survival to 17.7 months versus two months for apalutamide alone, a finding that could reshape how drug resistance is treated in prostate and lung cancers.

Found this article helpful?

Share it with your network and spread the knowledge!

Kairos Pharma's ENV-105 Interim Data Shows 17.7-Month Progression-Free Survival in Prostate Cancer Trial

Austin-based TinyGems reported that Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on addressing drug resistance in cancer, presented interim efficacy results for its lead candidate ENV-105 at the 11th International Conference on Cancer Research & Drug Development in Houston on Nov. 3, 2026. The presentation was delivered by President and Chief Scientific Officer Neil Bhowmick and carries implications that extend well beyond a single trial readout.

ENV-105 is a first-in-class CD105/BMP signaling inhibitor being evaluated in a Phase 1 trial for EGFR-driven non-small cell lung cancer and a Phase 2 trial in combination with apalutamide for metastatic castration-resistant prostate cancer, or mCRPC. An interim analysis of the Phase 2 trial demonstrated a statistically significant improvement in median progression-free survival among patients receiving ENV-105 plus apalutamide compared with apalutamide alone, with median PFS of 17.7 months versus two months, respectively (P=0.0008). That gap is the kind of differential that commands attention from clinicians and investors alike, because progression-free survival is a core measure of how long a treatment keeps disease in check.

The trial will now focus on first-line therapy after enzalutamide, incorporating first-line resistance in a larger patient group. Previous preclinical research has also demonstrated the potential of ENV-105 to enhance radiation sensitivity in prostate cancer models. Bhowmick said the findings support the company's hypothesis that targeting CD105 may interrupt mechanisms of treatment resistance and restore sensitivity to established cancer therapies. The logic matters for Texas and the wider oncology economy: resistance to standard therapy is a primary driver of relapse, and a candidate that restores the effectiveness of existing drugs could change treatment sequencing across multiple cancer types rather than replace current therapies outright.

Kairos Pharma, based in Los Angeles, California, utilizes structural biology to overcome drug resistance and immune suppression in cancer. Its lead candidate ENV-105 is an antibody targeting CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. The company's newsroom, which tracks ongoing updates relating to KAPA, is accessible through https://ibn.fm/KAPA, and the full press release is available at https://ibn.fm/PIrky.

TinyGems operates as a specialized communications platform for small-cap and mid-cap companies and is one of 75+ brands within the Dynamic Brand Portfolio at IBN. Its distribution infrastructure includes wire solutions through InvestorWire and editorial syndication to 5,000+ outlets, channels that determine how quickly a data point like the ENV-105 interim analysis reaches the investors and clinicians who act on it. For a clinical-stage company, that speed of dissemination is part of the commercial story.

The broader takeaway for Texas readers is structural. Houston hosted the conference where these results were unveiled, reinforcing the state's position as a venue where cancer research translates into business and investment activity. A statistically significant PFS benefit in a resistant prostate cancer setting, paired with an active lung cancer program, gives Kairos Pharma a clinical narrative that could influence partnership discussions and capital formation in the oncology sector. Full terms of use and disclaimers applicable to TinyGems content are posted at https://www.TinyGems.com/Disclaimer.